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Epigenome-wide analysis in newborn blood
spots from monozygotic twins discordant
for cerebral palsy reveals consistent
regional differences in DNA methylation
Namitha Mohandas1,2†, Sebastian Bass-Stringer1†, Jovana Maksimovic2,3, Kylie Crompton2,4,5, Yuk J. Loke1,
Janet Walstab2,4, Susan M. Reid2,4,5, David J. Amor2,4,5, Dinah Reddihough2,4,5 and Jeffrey M. Craig1,2,6*
Abstract
Background: Cerebral palsy (CP) is a clinical description for a group of motor disorders that are heterogeneous with
respect to causes, symptoms and severity. A diagnosis of CP cannot usually be made at birth and in some cases may
be delayed until 2–3 years of age. This limits opportunities for early intervention that could otherwise improve long-
term outcomes. CP has been recorded in monozygotic twins discordant for the disorder, indicating a potential role of
non-genetic factors such as intrauterine infection, hypoxia-ischaemia, haemorrhage and thrombosis. The aim of this
exploratory study was to utilise the discordant monozygotic twin model to understand and measure epigenetic changes
associated with the development of CP.
Methods: We performed a genome-wide analysis of DNA methylation using the Illumina Infinium Human Methylation
450 BeadChip array with DNA from newborn blood spots of 15 monozygotic twin pairs who later became discordant for
CP. Quality control and data preprocessing were undertaken using the minfi R package. Differential methylation analysis
was performed using the remove unwanted variation (RUVm) method, taking twin pairing into account in order to
identify CP-specific differentially methylated probes (DMPs), and bumphunter was performed to identify differentially
methylated regions (DMRs).
Results: We identified 33 top-ranked DMPs based on a nominal p value cut-off of p < 1 × 10−4 and two DMRs
(p < 1 × 10−3) associated with CP. The top-ranked probes related to 25 genes including HNRNPL, RASSF5, CD3D
and KALRN involved in immune signalling pathways, in addition to TBC1D24, FBXO9 and VIPR2 previously
linked to epileptic encephalopathy. Gene ontology and pathway analysis of top-ranked DMP-associated genes
revealed enrichment of inflammatory signalling pathways, regulation of cytokine secretion and regulation of
leukocyte-mediated immunity. We also identified two top-ranked DMRs including one on chromosome 6 within the
promoter region of LTA gene encoding tumour necrosis factor-beta (TNF-β), an important regulator of inflammation
and brain development. The second was within the transcription start site of the LIME1 gene, which plays a key role in
inflammatory pathways such as MAPK signalling. CP-specific differential DNA methylation within one of our two top
DMRs was validated using an independent platform, MassArray EpiTyper.
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Conclusions: Ours is the first epigenome-wide association study of CP in disease-discordant monozygotic twin pairs
and suggests a potential role for immune dysfunction in this condition.
Keywords: Cerebral palsy, DNA methylation, Inflammation, Epigenetics, Discordant twins
Background
Cerebral palsy (CP) describes a group of motor impairment
syndromes caused by lesions or anomalies of the developing
brain [1]. It is non-progressive, but the severity of symptoms
may change over time [2]. CP is the most common child-
hood physical disability [3] with a worldwide prevalence of
2.11 per 1000 live births [4]. In preterm infants (< 37 weeks
gestation), the prevalence is higher, ranging from 5 to 92
per 1000 depending on gestational age [5]. The prevalence
of CP in multiple births is almost four times that of single-
tons [6]. There are many factors that may be responsible for
this increased risk in multiple birth pregnancies, with the
most likely being low birth weight and preterm birth, both
known risk factors for CP.
The brain insult or anomaly resulting in CP may occur
during the prenatal, perinatal or early postnatal period [1, 7],
and in many cases, the timing is unknown. Although new-
borns may be recognised as being at risk of CP, less than half
of all children who are ultimately diagnosed are identified
before 1 year of age, and only three quarters are identified
before age 2 [8].
CP has a multifactorial pathogenesis and risk factors
including intrauterine growth restriction or infection,
placental abnormalities, inflammation, signs of fetal
distress and genetic variation [9, 10]. Although the latter
explains a proportion of CP cases, particularly cerebral
maldevelopments [9, 11, 12], many non-genetic factors
likely play a role [7] though their respective contribu-
tions have not been comprehensively addressed [13–15].
Genetically identical monozygotic (MZ) twin pairs dis-
cordant for CP highlight the role of non-shared factors in
the pathogenesis of CP [16]. Non-shared factors are often
described as the differences in the intrauterine environ-
ment that influences the development of individual mem-
bers of a twin pair [17, 18]. Such within-pair variation can
arise from differences in the length and morphology of the
umbilical cord or placenta. This can affect growth rate
and development of the individual twins leading to dis-
cordance in infection or inflammation, leading to disease
discordance [13, 19, 20]. More generally, the study of
phenotypically discordant MZ twins, matched for genetic
variation, sex, gestational age and maternal factors, pro-
vides a great opportunity to examine the role of epigenet-
ics in disease aetiology by allowing us to isolate the effect
of such non-shared environmental factors [21, 22].
Epigenetics refers to a range of modifications and
processes that regulate the activity of DNA, including
gene expression. Epigenetic variation has emerged as a
candidate mediator of a range of health outcomes begin-
ning in early life as part of the ‘Developmental Origins
of Health and Disease’ (DOHaD) phenomenon. [23–25].
In DOHaD, environmental conditions in utero and
during infancy alter the developmental trajectory of an
individual, which manifests as specific chronic health
phenotypes later in life.
DNA methylation is the most widely studied epigenetic
process and is one of the mechanisms that are involved in
tissue differentiation during early development. Despite
this, previous studies have investigated the concordance in
DNA methylation state between the brain and periph-
eral tissues, revealing many similarities [26–28]. Several
epigenome-wide association studies (EWAS) have iden-
tified DNA methylation variation in the cord blood in
association with later neurocognitive function and
behaviour [29–31]. Similarly, the whole blood has been
used to detect differential methylation patterns between
affected and unaffected individuals in brain disorders
such as schizophrenia [27], bipolar disorder [32, 33]
and Alzheimer’s disease [34]. Animal studies have also
reported that environmental factors affecting brain
processes leave biomarker signatures in the blood with
consistent methylation status across the brain and
peripheral tissues [35]. We have previously shown that
DNA methylation varies within pairs of MZ twins from
birth [36, 37]. In this study, we hypothesised that early
life non-shared factors that play a role in the aetiology
of CP in discordant MZ twins may be reflected in
differences in DNA methylation across tissues including
neonatal blood. Furthermore, we hypothesised that a
subset of differential methylation will be located in
genes previously implicated in CP aetiology [38–42], in
particular, pathways involved in inflammation, hypoxia-
ischaemia and thrombosis.
Methods
Samples and DNA extraction
Participant CP-discordant twin pairs, who were suspected
to be MZ on the basis of same sex and questionnaire data
that measured concordance for hair and eye colour, were
recruited through the Victorian Cerebral Palsy Register, a
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population-based registry of individuals born or receiving
medical services in the Australian state of Victoria. Partici-
pants were excluded if either twin presented with another
known neurological disorder. Written informed consent
from the families was obtained. A single 1-cm-diameter
dried blood spot was acquired from all participants from a
neonatal newborn screening card collected 2 to 4 days
after birth and then stored within the Victorian Clinical
Genetics Service.
Genomic DNA (gDNA) was extracted from the dried
blood spot samples using the ZR DNA Card Extraction
Kit (Zymo Research, Irvine, CA, USA) with some modi-
fications to the manufacturer’s protocol. Briefly, eight
3-mm punches were from each 1-cm-diameter blood
spot and were transferred to a 2-mL Eppendorf Safe-Lock
microcentrifuge tube (Merck, Darmstadt, Germany) con-
taining ZR BashingBeads. Four hundred microliters of
PBS containing 40 μL of 20 mg/mL proteinase K (Sigma-
Aldrich, St. Louis, Missouri, USA) was added, and samples
were vortexed and centrifuged briefly, followed by incuba-
tion overnight at 37 °C. Following incubation, 400 μL of
ZR lysis solution was added to each tube. Punches were
homogenised for 30 s at 4 m/s2 using Thermo Savant
FastPrep 120 Cell Disrupter System (Global Medical
Instrumentation (GMI) Incorporation, Minnesota, USA).
Tubes were centrifuged for 1 min at 10,000 rpm, and
390 μL of 2× digestion buffer and 10 μL of 20 mg/mL
proteinase K were added. Tubes were mixed by inversion
and incubated for 30 min at 55 °C, then left to cool at
ambient temperature for 3–4 min before centrifuging for
1 min at 8000 rpm. Six hundred fifty microliters of
supernatant was added to 1.3 mL of DNA isolation buffer
contained in a 5-mL Falcon tube (Thermo Fisher
Scientific, MA, USA). This mixture was passed through
the Zymo-Spin IC column by centrifuging for 1 min at
14,000 rpm, followed by the discard of flow-through
liquid. The spin column was then washed twice by adding
200 μL of DNA wash buffer and centrifuged for 1 min at
14,000 rpm. Finally, 20 μL of DNA elution buffer (pre-
warmed at 55 °C) was added to the column and incubated
at ambient temperature for 15 min before final centrifuga-
tion for 2 min at 14,000 rpm. This was repeated, resulting
in a final elution volume of 40 μL containing genomic
DNA. DNA concentration was measured by spectropho-
tometry (Nanodrop, Wilmington, DE, USA) to allow
calculation of the required volume of each sample for
array analysis. The quality of the extracted gDNA samples
was visualised using agarose gel electrophoresis.
Illumina Infinium HumanMethylation450 arrays
Following bisulphite conversion of genomic DNA, genome-
wide analysis of DNA methylation was assessed using
HM450 (Illumina, San Diego, CA, USA), at the Department
of Pathology, University of Melbourne. Hybridisation and
scanning were performed following the manufacturer’s
instructions. Statistical analysis was performed using
the R statistical programming language (http://www.R-
project.org) in conjunction with Bioconductor packages
developed for the analysis of methylation arrays.
Preprocessing of Illumina Infinium 450K array data
The raw intensity data (IDAT files) were imported into R
(3.3.1; http://cran.r-project.org/). Data quality was
assessed using the minfi (v1.20.2) Bioconductor package
[43]. From 485,512 HM450 probes, 67,120 were re-
moved based on either (1) poor performance (mean de-
tection p value of > 0.01, n = 14,056); (2) probes
containing either a single nucleotide polymorphism
(SNP) at the target CpG site or at the single nucleotide
extension site (n = 16,307); (3) probes that map to mul-
tiple locations in the genome (n = 27,120), [44]; and (4)
or to sex chromosomes (n = 9637). Samples were also
evaluated using a modified version of the Houseman
method [45, 46] implemented in minfi, to estimate the
cell type composition. The Wilcoxon signed-rank stat-
istical test was used to compare the difference in cell
type proportion between CP cases and controls. The
analysis was completed before a cord blood reference
panel was widely available, so cohorts used an adult
whole blood reference [43] to estimate the proportion
of B cells, CD8+ T-cells, CD4+ T-cells, granulocytes,
NK cells and monocytes in each sample. The data was
normalised using subset-quantile within array normalisa-
tion (SWAN) [47]. Covariates such as birth weight, birth
order and postnatal age (in days) at which newborn
screening cards were created were assessed as potential
confounders.
Differential methylation analysis
Beta (β) values (proportion of the methylated signal over
the total signal) were converted to M-values, the log2 ratio
of the intensities of the methylated signal versus the
unmethylated signal. Differential methylation analysis was
performed using remove unwanted variation (RUVm) [48],
implemented in the missMethyl R package [49] taking into
account the twin relationships. RUVm is a data-driven
method of controlling for unwanted technical and bio-
logical variation in regression analyses using an empirically
determined set of negative control probes assumed not to
be associated with the biological factor of interest. p values
were adjusted to control for the false discovery rate (FDR)
using the Benjamini-Hochberg method [50]. Differentially
methylated probes (DMPs) were considered significant if
they fell within the FDR threshold of 0.1. We also investi-
gated the top-ranked DMPs with an unadjusted p value
less than 1 × 10−4 [51].
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Identification of differentially methylated regions
Differentially methylated regions (DMRs) were identified
using the bumphunter package [43, 52]. The cut-off
value, which is a user-defined numeric value that
determines the upper and lower bounds of the genomic
profiles that will be used as candidate regions, was set to
0.02 and the number of permutations set to 1000.
Functional annotation and pathway analysis
Gene ontology and pathway analysis were performed using
the gometh function from the missMethyl package [49],
which appropriately takes into account the variable number
of HM450 probes associated with each gene. Gene
ontology enrichment was performed for the 1000 top-
ranked DMP-associated genes. The KEGG option of the
gometh function in missMethyl was used to provide further
insights into relevant biological processes associated with
the top-ranked DMPs.
Validation of differentially methylated regions
Site-specific validation was performed using the Sequenom
MassArray EpiTYPER (Agena Biosciences). T7-tagged
primers were designed for two regions (Additional file 1)
using the Sequenom EpiDesigner package [53]. Forward
primer sequences contained a 10 base 5′ tag (AGGAAGA-
GAG) and reverse primers a 31 base 5′ tag (CAGTAA-
TACGACTCACTATAGGGAGAAGGCT). In silico, assay
prediction was performed using the BiocLite MassArray
package. DNA used for validation was the same as that
used for the HM450 analysis. Bisulphite treatment of
genomic DNA was accomplished using the MethylEasy
Xceed Kit (Human Genetic Signatures, North Ryde,
Australia). One microliter of bisulphite-converted product
was amplified in triplicate for each sample using the
FastStart kit (Roche, Mannheim, Germany) in 15 μL of
reagents with thermal cycling conditions as follows: 95 °C
for 10 min; 5 cycles of 95 °C for 10 s, 60 for 30 s and 72 °C
for 2 min; 40 cycles of 95 °C for 10 s, 62 for 30 s and 72 °C
for 90 s; and final extension at 72 °C for 7 min. Raw data
generated from the MassArray EpiTYPER was cleaned
using a Microsoft Excel macro developed in-house [54, 55].
The median value of triplicates was determined, and any
replicates > 10% from the median were removed as
previously described [54, 55].
Within-twin pair analysis
To explore the top-ranked CpGs within each twin pair
and compare them across twin pair groups, probes were
ranked according to delta beta (Δβ, the difference in
DNA methylation of the CP minus non-CP twin) within
pairs, and the top-ranked 100 probes were compared
across all 15 twin pairs. The genes corresponding to all
probes with a Δβ value > 0.5 were then compared across
the 15 twin pairs. Gene ontology analysis was performed
on the top 1000 probes from each twin pair, and
common ontologies between twin pairs were identified.
Results
Subject characteristics
The study cohort consisted of 16 CP-discordant twin
pairs (ten male and six female) for which pre-screening
suggested a high probability of monozygosity (Table 1).
All were tested for genetic zygosity using data from 65
SNPs from the Infinium arrays. The variability of SNPs
for one twin pair (pair no. 9003) was substantially larger
than the remaining samples and was therefore assigned
as dizygotic (DZ). This pair was excluded from further
analysis. Five subtypes of CP were reported: spastic
diplegia (6), spastic quadriplegia (3), spastic hemiplegia
(3), dyskinesia (2) and ataxia (1). The severity of CP
ranged from mild (independently ambulant) to severe
(wheelchair dependent), and the underlying neuro-
pathology included white matter (11), grey matter brain
injury (2) and both white and grey matter mixed injury
(2). Three twin pairs were born at term (37–41 weeks),
while all other twin pairs were born preterm (< 37 weeks).
Global DNA methylation profiles in CP-discordant mono-
zygotic twins
Global DNA methylation (average β value across all
probes) within twin pairs was compared using a pairwise
Pearson correlation for the 418,392 probes remaining
after filtering and quality control (see the ‘Methods’
section) for all 15 twin pairs. Within-pair methylation
Table 1 Descriptive characteristics of the study cohort
Twin ID Type of CP Gestational age (weeks) Brain Injury
9001 Spastic diplegia 27 (Preterm) WMI
9002 Spastic diplegia 28 (Preterm) WMI
9003* Spastic diplegia 29 (Preterm) WMI
9004 Spastic diplegia 29 (Preterm) WMI
9005 Spastic quadriplegia 31 (Preterm) WMI
9006 Spastic diplegia 32 (Preterm) WMI
9007 Spastic hemiplegia 32 (Preterm) WMI
9008 Spastic quadriplegia 33 (Preterm) WMI
9009 Spastic diplegia 33 (Preterm) WMI
9010 Spastic diplegia 36 (Preterm) M
9011 Dyskinetic: dystonic 38 (Term) GMI
9012 Dyskinetic: hypotonia 32 (Preterm) WMI
9013 Spastic quadriplegia 38 (Term) M
9014 Ataxia 34 (Preterm) GMI
9015 Spastic hemiplegia 32 (Preterm) WMI
9016 Spastic hemiplegia 38 (Term) WMI
WMI white matter injury, M miscellaneous, GMI grey matter injury
*Twin pair 9003 was later confirmed not to be MZ and removed from the analysis
Mohandas et al. Clinical Epigenetics  (2018) 10:25 Page 4 of 15
correlation coefficients ranged from 0.980 to 0.996
(Additional file 2) compared to 0.976 to 0.995 between
unrelated unaffected individuals.
Top-ranked CP-associated DMPs
Cleaned data was explored by principal component (PC)
analysis which revealed few (6/54) significant correlations
(p < 0.05, r < 0.6 shaded in Additional file 3) between the
top six principal components of DNA methylation and
nine technical (e.g. age at which Guthrie card was created)
and biological (e.g. sex, subtype of CP) covariates. This
suggested that none of the covariates tested was consist-
ently associated with DNA methylation. In addition, none
were associated with the largest principal component of
variation within the dataset, PC1. Multi dimensional scal-
ing (MDS) plots of the first three dimensions of the proc-
essed methylation data also showed that chip location and
position on the 450K array were not found to affect
methylation data (Additional file 4).
Apart from the above covariates, it is known that cell-
type heterogeneity within the whole blood can confound
epigenome-wide analyses. Therefore cell-type composition
within CP-discordant pairs was evaluated. The levels of
CD8+ T cells (CD8T) and CD4+ T cells (CD4T), B cells,
natural-killer (NK) cells, monocytes and granulocytes were
compared between the two groups (CP cases and normal
co-twins). There was no statistically significant difference
in the estimated cell-type proportions of CD8+ T cells, NK
cells, B cells and monocytes (p > 0.05). However, the
proportion of CD4+ T cells was lower (p = 0.002), and the
proportion of granulocytes was found higher (p = 0.021) in
CP cases relative to normal co-twins (Additional file 5).
To take into account potential sources of unwanted
variation (such as cell-type composition), the genome-
wide analysis was performed using RUVm, which adjusts
for biological and technical variation using a set of data-
driven negative control probes [46, 48, 56, 57]. This
analysis did not identify any significant CP-associated
DMPs after adjusting for multiple testing. Nevertheless,
as this is an exploratory epigenome-wide study of CP, we
focused on the characteristics of the top-ranked DMPs
based on a nominal p-value cut-off of p < 1 × 10−4 as
used by others [51]. This resulted in a list of 33 top-
ranked DMPs, corresponding to 25 genes (Table 2),
most of which showed a consistent direction in the ma-
jority of twin pairs (> 12/15). The average difference in
methylation (Δβ = CP twin minus unaffected twin)
ranged from + 0.6 to + 11.9% and from − 2.5 to − 12.4%
(Table 2). Figure 1 shows the within-pair differences in
methylation for the top ten DMPs.
The top-ranked probe cg00376816 (average Δβ = 11.6%,
p = 4.57 × 10−6) was located on chromosome 19, within
the gene body of the HNRNPL gene encoding the
heterogeneous nuclear ribonucleoprotein L. Others
included cg04242728 (in the 5′ end of the TBC1D24
gene, ranked 3) and cg19607845 (in the gene body of
FBXO9 gene, ranked 13). Probes located near the
gene body of immune and inflammatory genes, such
as Ras association domain family member 5 (RASSF5),
major histocompatibility complex DM alpha-chain
(HLA-DMA), CD3D and kalirin (KALRN) genes, were
also among the top-ranked 33 DMPs.
To identify enriched biological processes or molecular
functions, we performed gene ontology analysis on genes
associated with the top-ranked 1000 DMPs. The top 20
gene ontologies ranked by nominal p-value were ‘regulation
of immune response’, ‘lymphocyte activation’, ‘differentiation
and aggregation and T cell activation’ with the top two
ontologies related to cell-cell adhesion processes (Table 3;
Additional file 6). Enriched disease pathways, as reported
by KEGG analysis, included MAPK signalling (19 associated
genes from 245 genes in the KEGG pathway list; p value
3.6 × 10−10), cytokine-cytokine receptor interaction (13 as-
sociated genes from 240 genes; p value 1.3 × 10−08) and Ras
signalling (15 associated genes from 218 genes; p value:
9.8 × 10−08).
We also identified DMRs associated with CP [52]
(Table 4). The top-ranked DMR, spanning 434 bp and
with a p value of 5.6 × 10−4, was located on chromosome 6
(Fig. 2). This DMR spans 12 probes (average Δβ = 3.7%)
within the coding region of the LTA gene, approximately
~ 800 bp downstream of the transcription start site (TSS).
LTA codes for the lymphotoxin-alpha protein otherwise
known as tumour necrosis factor beta (TNF-β). Other top
DMRs include those within LTBP1, CD300, CHST11 and
LIME1. Gene ontology analysis of the top-ranked
DMR-associated genes revealed similar findings to top-
ranked DMPs (Table 5; Additional file 7). We found an
over-representation of inflammatory signalling path-
ways, also similar to that of the top-ranked DMPs. The
top pathways included TNF and TGF-beta signalling
and cytokine-cytokine receptor interaction. The nuclear
factor kappa-light-chain-enhancer of activated B cell
(NF-κB) signalling pathway was also enriched.
Validation of DMRs
LIME1 and LTA DMRs were selected for validation as
they were highly ranked, had large, consistent effect sizes
across all pairs and were biologically relevant to CP.
Three CpGs from the HM450 platform contained within
three CpG units on the MassArray Epityper (consisting
of seven CpG sites in total) were tested for the LIME1
DMR, and four CpGs contained within three units on
the MassArray Epityper (four CpG sites in total) were
tested for the LTA DMR, both in regions being approxi-
mately 200 base pairs upstream of the transcriptional
start site (TSS200) and likely to be in gene promoters.
Scatter plots were generated to assess the validity of the
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data for the three LIME1 and LTA probes within a 250-
base-pair region across both the HM450 and the EpiTYPER
platforms (Additional file 8). Pearson’s correlation coeffi-
cients were determined, and the significance of the
correlation was assessed for each probe-CpG unit
comparison. Five out of six probes (cg21201401,
cg06653796, cg14597739, cg11586857, cg21999229) had
a positive correlation between the two platforms.
Among these, one probe out of three for LIME1 and
two of three for LTA had moderate correlations (r > 0.5).
All moderate correlations were also significant with p < 0.05
(r = 0.88, p = 1.6 × 10−4; r = 0.40, p = 0.197; r = 0.12, p = 0.65
for LIME1 and r = 0.69, p = 1.4 × 10−4; r = 0.59, p = 0.043;
r = 0.21, p = 0.34 for LTA.). The Δβ values were calculated
for two of the three probes within the LTA gene region,
with correlation coefficient values of r = 0.69 for
cg14597739 and r = 0.21 for cg21999229. The Δβ for probes
within the LIME1 gene region were not calculated
due to insufficient data points, resulting from limited
material remaining, for a valid within-pair analysis.
Differential methylation analysis within individual twin pairs
Since CP is a highly heterogeneous disorder [58], it is pos-
sible that a subset of disease-associated DNA methylation
Table 2 The top-ranked DMPs (ranked on unadjusted p value) in cerebral palsy discordant twins
Probe ID Rank Chromosome position Gene Location P value Methylation difference (%)
cg00376816 1 chr19: 39332571 HNRNPL 4.57E-06 11.64
cg25011252 2 chr8: 61777859 CHD7 6.33E-06 7.64
cg04242728 3 chr16: 2536153 TBC1D24 1.46E-05 − 8.20
cg03907855 4 chr8: 1106363 – Island 1.52E-05 − 3.20
cg05707458 5 chr1: 205424829 – Island 1.93E-05 2.39
cg18369327 6 chr5: 109220986 LOC100289673 2.07E-05 − 2.54
cg18768238 7 chr10: 49892829 WDFY4 2.52E-05 − 8.58
cg14163311 8 chr1: 206730397 RASSF5 3.21E-05 8.20
cg16602500 9 chr1: 52889575 ZCCHC11 3.64E-05 6.25
cg06419846 10 chr11: 66083572 CD248 3.65E-05 5.95
cg03929569 11 chr13: 30688864 – Island 4.35E-05 0.60
cg14414943 12 chr1: 111770718 CHI3L2 4.65E-05 6.21
cg19607845 13 chr6: 52930050 FBXO9 4.79E-05 − 9.61
cg19942731 14 chr22: 45609421 C22orf9 5.11E-05 − 10.38
cg14073571 15 chr7: 158823178 VIPR2 5.14E-05 − 7.59
cg03106245 16 chr11: 47399788 SPI1 5.33E-05 − 11.45
cg08936645 17 chr4: 37910273 TBC1D1 5.36E-05 − 7.84
cg02806715 18 chr6: 32920567 HLA-DMA 5.69E-05 − 6.58
cg17512380 19 chr10: 18971598 – OpenSea 5.81E-05 5.67
ch.10.89216809R 20 chr10: 89226829 – OpenSea 6.52E-05 − 3.85
cg15613292 21 chr2: 232478359 – Shore 6.89E-05 2.62
cg00263248 22 chr14: 98444151 C14orf64 6.94E-05 6.40
cg19540797 23 chr2: 3605489 RNASEH1 7.30E-05 2.27
cg08360638 24 chr13: 20781097 – OpenSea 7.52E-05 7.09
cg07728874 25 chr11: 118213272 CD3D 7.93E-05 9.14
cg11348257 26 chr1: 76556226 ST6GALNAC3 8.03E-05 − 12.35
cg07011093 27 chr3: 123987726 KALRN 8.38E-05 − 5.03
cg09335613 28 chr6: 71998106 OGFRL1 8.85E-05 − 6.68
cg22230912 29 chr3: 16331335 OXNAD1 8.90E-05 11.86
cg13505608 30 chr9: 140128562 SLC34A3 9.22E-05 2.53
cg04975778 31 chr2: 62732758 TMEM17 9.26E-05 2.31
cg12306086 32 chr4: 106117747 TET2 9.52E-05 − 10.22
Methylation difference (%) was calculated as the mean of the DNA methylation levels of the CP twin minus the unaffected twin (Δβ)
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patterns may be specific to each proband. To test this
[59], we determined the top CP-associated CpGs for each
twin pair ranked by absolute differences in DNA methyla-
tion (Δβ > 0.5) and looked at significant gene ontologies
common to multiple pairs (Additional file 9). Gene ontol-
ogies corresponding to cell adhesion were found in 5/15
twin pairs (Additional file 10). Similarly, common CpGs
with a within-pair methylation difference > 50% were found
in multiple twin pairs (Table 6) in genes such as BICD2,
HLA-DPB2, RPTOR and PIK3CG (Additional file 11), in-
volved in neuronal cell migration, muscular atrophy or
muscle contraction pathways and immune response and in-
flammatory pathways, respectively [60–63]. Notably, two
different CpG sites within twin pairs 4 and 8 corresponding
to the WWTR1 gene had an absolute methylation differ-
ence of greater than 50% with the same direction of effect.
Affected CpG sites were located near the 5′ end of the gene
in both pairs (Table 6).
Discussion
This exploratory study represents an initial step towards
investigating potential CP-associated epigenetic differ-
ences, with the longer-term aim of identifying predictive
biomarkers with clinical utility. We identified DNA
methylation differences in dried blood spots from 15
CP-discordant MZ twin pairs and found differential
methylation at several gene loci associated with hypoxia
signalling, inflammation and cell adhesion. These path-
ways had been previously linked to CP, consistent with
part of our hypothesis.
Pairwise global DNA methylation difference between
CP and non-CP members of each pair measured for
Fig. 1 DNA methylation differences (CP minus normal twin) for the top ten CP-specific DMPs. The direction of methylation difference for each probe was
consistently in the same direction (hyper- or hypomethylated) across > 12/15 twin pairs. The dotted line represents the average methylation difference,
and methylation difference is represented in absolute value (effect size of 0.1 is 10% methylation difference)
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each twin group and comparison of the size of DNA
methylation difference made between groups allowed
for an assessment of how variable the differences in
methylation may be for different cases of CP. Our
results are consistent with previous studies (e.g. [59])
that have indicated that neurodevelopmental disorders
such as autism spectrum disorder are not associated
with systemic within-twin pair differences in global
DNA methylation.
We tested site-specific DNA methylation patterns
across the genome for their association with CP,
taking CP status within discordant MZ pairs into
account. Although no probe reached an adjusted
statistical significance at FDR < 0.1, the top-ranked
DMPs, at a nominal cut-off of p < 1 × 10−4, were
enriched for the cellular processes of inflammation,
cell adhesion and immune response. These showed
the direction of effect across most or all discordant
twin pairs. This was in accordance with EWAS of
other neurodevelopmental disorders including twins
discordant for autism spectrum disorders [59], asthma
[51], depression [64] and aggressive behaviour [65].
Table 3 Top 20 gene ontology (GO) terms (BP = biological process) analysed for the 1000 top-ranked CP-associated DMPs
GO ID GO term Ontology No. of genes DM genes Unadjusted p value
GO:0098609 Cell-cell adhesion BP 1091 90 8.27E-06
GO:0007156 Homophilic cell adhesion via plasma membrane adhesion molecules BP 149 25 1.70E-05
GO:0042098 T cell proliferation BP 157 18 2.91E-05
GO:0042129 Regulation of T cell proliferation BP 133 16 3.28E-05
GO:0046649 Lymphocyte activation BP 557 46 6.47E-05
GO:0032729 Positive regulation of interferon-gamma production BP 58 10 7.55E-05
GO:0070661 Leukocyte proliferation BP 241 23 9.24E-05
GO:0001775 Cell activation BP 811 61 9.70E-05
GO:0050863 Regulation of T cell activation BP 270 26 1.27E-04
GO:0022610 Biological adhesion BP 1611 117 1.28E-04
GO:1903037 Regulation of leukocyte cell-cell adhesion BP 284 27 1.30E-04
GO:0070663 Regulation of leukocyte proliferation BP 187 19 1.66E-04
GO:0045321 Leukocyte activation BP 656 50 1.93E-04
GO:0007159 Leukocyte cell-cell adhesion BP 442 37 2.27E-04
GO:0098742 Cell-cell adhesion via plasma-membrane adhesion molecules BP 214 27 2.32E-04
GO:0050865 Regulation of cell activation BP 437 37 2.37E-04
GO:0016337 Single organismal cell-cell adhesion BP 669 54 2.49E-04
GO:0032649 Regulation of interferon-gamma production BP 85 11 2.51E-04
GO:0007155 Cell adhesion BP 1606 115 2.56E-04
GO:0045601 Regulation of endothelial cell differentiation BP 28 7 2.75E-04
DM differentially methylated, FDR false discovery rate
Table 4 Differentially methylated regions (DMRs) from Bumphunter analysis
Chromosome position Gene Gene description P value Fwer
chr6: 31539735-31540169 LTA Lymphotoxin-alpha 0.00056 0.988
chr12: 31799116-31799118 – – 0.00125 0.992
chr11: 47399813-47400146 SPI1 Spi-1 Proto-Oncogene 0.00129 0.996
chr2: 33359198-33359688 LTBP1 Latent transforming growth factor beta binding protein 1 0.00166 0.996
chr17: 72527607-72527724 CD300LB CD300 molecule like family member b 0.00244 0.996
chr12: 105071483-105071483 CHST11 Carbohydrate chondroitin 4 sulfotransferase 11 0.00259 0.996
chr9: 130868874-130868874 SLC25A25 Solute carrier family 25 member 25 0.00269 0.996
chr11: 2722062-2722195 KCNQ1 Potassium voltage-gated channel subfamily Q member 1 0.00164 1
chr1: 27961563-27962037 FGR FGR proto-oncogene, Src family tyrosine kinase 0.00223 1
chr20: 62367805-62367893 LIME1 Lck interacting transmembrane adaptor 1 0.00167 1
fwer family-wise error rate
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Average within-pair DNA methylation differences of
up to 12.5% were observed, comparable to previous
findings in neurodevelopmental disorders, ranging
from 1.5 to 12%. Furthermore, we validated five of
the six CpG probes, with positive correlations across
platforms. Three of these five probes (one from
LIME1 and two from LTA) showed a strong and sig-
nificant cross-platform correlation, indicating the val-
idity of methylation values between platforms.
Genes associated with top-ranked DMPs and DMRs
were enriched for similar ontologies and pathways, namely
immune response, lymphocyte-mediated immunity, interferon-
gamma production and regulation of immune response.
Our study revealed top-ranked DMRs associated with
genes that play a role in inflammation, such as LTA/TNFβ
and LIME1, supporting part of our hypothesis that inflam-
mation plays a key role in CP aetiology. Genetic variants of
LTA have been implicated in multiple studies as being associ-
ated with risk for CP [66–68]. LTA plays an important role
in inflammation and brain development, mediating preterm
birth and white matter brain injury [69]. It has been impli-
cated that inflammation [70] and increased levels of its iso-
form TNF-α were found in children with CP compared to
healthy controls [71]. LIME1 gene links T and B cell signal-
ling to the activation of tyrosine and MAP kinases [72].
Other top DMR-associated genes such as LTBP1 and CD300
are also known mediators of inflammatory pathways such as
ERK signalling pathway, interleukin-3,-5 pathway, B cell re-
ceptor signalling pathway and other chemokine signalling
[72–74]. Genes associated with top-ranked DMPs also
showed involvement in other key inflammatory pathways
such as Ras signalling (WDFY4), MAP kinase signalling
(CD3D) and interleukin-3,-5 signalling (KALRN). Analysis
within individual twin pairs also revealed associations to the
WWTR1 gene, which is involved in the activation of TGF-β
signalling pathway, an inflammatory pathway that regulates
neural survival and death [75, 76]. Gene ontology analysis of
top-ranked DMPs showed enrichment of genes involved in
regulation of immune response pathways such as those in-
volved in signalling or T-cell activation. It is noteworthy that
Fig. 2 Schematic representation of the top-ranked DMR (LTA). The genomic coordinates are plotted on the top lane using the version hg19 of the UCSC
genome browser (https://genome.ucsc.edu), where each division is 200 base pairs. Mean beta values for CP (red line) and normal (green lines) twins are
plotted on the next lane. The light blue box indicates the differentially methylated region. DNase I hypersensitive sites is plotted in subsequent lane. The
DNase I hypersensitive site data was obtained from the UCSC Genome Browser, and the dark blue boxes represent the characterised gene based on
reference sequence. The vertical blue lines on the genome browser map indicate the three CpG units validated on MassArray EpiTYPER
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intrauterine infection is a known risk factor for CP and that
many inflammatory cytokines have been shown to be critical
to the risks associated with CP [38, 41, 60].
Perinatal brain injury can be induced by a range of
insults such as hypoxic-ischaemic injury or infection [77].
An in utero infection such as chorioamnionitis may trig-
ger an innate immune response, resulting in elevated cyto-
kine levels. Cytokines in the fetal blood may contribute to
a systemic fetal inflammatory response with eventual
penetration across the blood-brain barrier resulting in an
inflammatory cascade in the fetal brain [78]. Brain injury
induced by neonatal hypoxia-ischaemia also involves key
components of inflammation such as immune cells,
chemokines, cytokines and cell adhesion molecules [79].
Therefore, we suggest that inflammation may play a role
in perinatal brain damage associated with CP.
We also observed an enrichment of CP-associated
DMPs and DMRs in gene ontologies associated with cell
adhesion, and this was also observed in individual twin
pairs. Aberrant expression of cell adhesion molecules
has been reported in muscle biopsies of both children
and adults with CP [39]. Previous whole exome and
whole genome sequencing studies have also illustrated
the potential role of cell adhesion in CP by identifying
genetic variants in novel candidate genes which function
as neural adhesion molecules essential for neurite out-
growth and axon guidance [9, 12]. The NF-κB transcrip-
tion factor signalling pathway was common in both
DMPs and DMRs.
Our results are consistent with a previous gene expres-
sion study in newborn blood spot samples from children
with CP [80], which identified up-regulation of inflam-
matory pathways in preterm children who later developed
the disorder. Other similarities between the two studies
include variation in genes involved in T-cell and B-cell
receptor signalling pathways and cytokine-cytokine receptor
interaction, all of which were shown to have a dysregulation
in CP cases [80]. However, we found no evidence for an
association with increased thyroid function in preterm-born
CP cases as hypothesised and reported previously [80].
Another top-ranked DMP was HNRNPL, which likely
plays a role in response to hypoxia via regulation of the vas-
cular endothelial growth factor (VEGF) gene [81]. Hypoxia
is known to hinder normal development and maturation of
the brain and can cause white matter injury in preterm
born infants [82] resulting in CP [83]. This finding supports
our hypothesis that epigenetic alterations in genes involved
in hypoxic pathways play a role in the aetiology of CP.
Table 5 Gene ontology (GO) analysis for cerebral palsy-associated DMRs. (DM: differentially methylated; FDR: false discovery rate)
GO ID GO term Ontology No. of genes DM genes Unadjusted p value FDR
GO:0002705 Positive regulation of leukocyte mediated immunity BP 80 5 4.57E-10 9.60E-06
GO:0002703 Regulation of leukocyte mediated immunity BP 139 5 7.48E-09 5.26E-05
GO:0002699 Positive regulation of immune effector process BP 142 5 7.52E-09 5.26E-05
GO:0050715 Positive regulation of cytokine secretion BP 91 4 8.69E-08 4.56E-04
GO:0002443 Leukocyte mediated immunity BP 258 5 1.42E-07 5.95E-04
GO:0002697 Regulation of immune effector process BP 291 5 4.04E-07 1.09E-03
GO:0042742 Defence response to bacterium BP 204 4 4.13E-07 1.09E-03
GO:0050778 Positive regulation of immune response BP 571 6 4.17E-07 1.09E-03
GO:0050707 Regulation of cytokine secretion BP 135 4 5.96E-07 1.39E-03
GO:0050663 Cytokine secretion BP 154 4 9.84E-07 2.06E-03
GO:0001819 Positive regulation of cytokine production BP 360 5 1.32E-06 2.52E-03
GO:0002876 Positive regulation of chronic inflammatory Response
to antigenic stimulus
BP 2 2 1.61E-06 2.81E-03
GO:0050776 Regulation of immune response BP 769 6 1.82E-06 2.82E-03
GO:0002682 Regulation of immune system process BP 1191 7 1.88E-06 2.82E-03
GO:0002874 Regulation of chronic inflammatory response to
antigenic stimulus
BP 3 2 2.15E-06 3.00E-03
GO:0050830 Defence response to Gram-positive bacterium BP 68 3 2.45E-06 3.22E-03
GO:0002925 Positive regulation of humoral immune response
mediated by circulating immunoglobulin
BP 4 2 2.82E-06 3.48E-03
GO:0002678 Positive regulation of chronic inflammatory response BP 4 2 3.23E-06 3.76E-03
GO:0002718 Regulation of cytokine production involved in
immune response
BP 52 3 3.84E-06 4.24E-03
GO:0002684 Positive regulation of immune system process BP 820 6 4.24E-06 4.44E-03
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Two high-ranking DMPs lie within the TBC1D24 and
FBOX9 genes respectively, and both have previously
been associated with epilepsy [84, 85]. In 29% of CP
cases in Victoria, Australia, epilepsy is comorbid with
CP [5]. These results may suggest a potentially shared
aetiology between epilepsy and CP [86, 87].
Our findings agree with those of others showing a link
between early life DNA methylation state and neurodeve-
lopmental and cognitive outcomes [29, 88], which would
allow for early diagnosis and facilitate timely intervention.
Currently, MRI scans, assessment tests such as the General
Movements Assessment and interventions such as environ-
mental enrichment, early developmental, early motor and
physiotherapy interventions are used to inform strategies
for early intervention in high-risk groups, such as preterm
born children, [89–93].
Given that CP is a highly heterogeneous condition, this
study highlights the importance of using epigenetic
biomarkers to distinguish and detect underlying path-
ways across the disorder. For individuals, such an epi-
genetic state at birth could be used to estimate risk for
subsequent development of overt CP.
The strength of using MZ twins is that they are
matched for parental age, age, sex, season of birth and
genetic factors. Although twins have a higher risk of CP
than singletons, the causative mechanisms, such as
thrombosis, and infection in the mother, the placenta or
the umbilical cords are likely to be similar [7]. Studying
twins discordant for CP allows genetic and environmental
components to be partitioned from each other and
provides a unique opportunity to evaluate the importance
of non-shared environmental factors such as umbilical
cord or placental function during early development in
isolation. It is possible that only twin of a pair may develop
an infection or inflammation of the umbilical cord or
placenta ([13, 19, 20, 94]). Such non-shared environmental
factors are known to influence the development of
individual members of a twin pair. This pilot study also
highlights the importance of analysing DNA methylation
in dried blood spots, which are collected at birth and
stored by many countries and the potential for developing
future predictive diagnostic tests [55, 95, 96].
Although each tissue has a subset of CpGs whose DNA
methylation patterns are tissue-specific, DNA methylation
changes that are concordant between the blood and brain
have been detected in previous studies [32, 97, 98]. One ex-
ample is where they identified parallel changes in DNA
methylation between the brain and blood in 30% of the genes
implicated in Parkinson’s disease [98]. It was also shown that
a DNA methylation module exists in key ageing-related regu-
latory genes both in the brain and blood [99]. In addition,
animal studies have reported that an early environment
resulting in a brain disorder can alter DNA methylation in
the same gene across the brain and peripheral tissues [35].
There are some limitations to this study. While similar
in sample size to many comparable twin studies of
brain-related disorders [58, 59, 64, 100], we acknowledge
that larger sample sizes of 25 twin pairs or more are
preferable to detect a mean effect size of at least 8%
methylation (FDR = 0.05) [101]. As CP is a heteroge-
neous condition, the small sample size of our cohort,
with a lack of CP concordant and healthy twin pairs for
comparison, also limits our capability to understand the
biological mechanisms of brain injury that may be
specifically associated with CP subtype. The use of
peripheral tissue and blood also limits our capability to
pinpoint the mechanism of CP. Despite the fact that the
brain and blood arise from separate cell lineages, and
are thought to be epigenetically distinct, many epigenetic
studies are often conducted in the blood due to ease of
availability [102]. Previous investigations of methylomic
variation across the blood and brain tissue from different
Table 6 Genes/probes with an absolute methylation difference
of > 50% common to multiple twin pairs
Twin pair group Methylation difference Common genes
TW7 0.784 MED27 (cg26228569)
TW15 − 0.749
TW5 0.824 BICD2 (cg14341177)
TW6 − 0.796
TW7 0.705
TW1 0.534 HLA-DPB2 (cg01309395)
TW2 − 0.627
TW11 0.693
TW10 0.585
TW2 − 0.768 CNOT6L (cg11671265)
TW4 0.745
TW2 0.634 SIM1 (cg00736459)
TW4 0.556
TW2 − 0.752 NR2C2 (ch.3.343413R)
TW14 0.584
TW2 0.753 LRP11 (cg24761195)
TW16 0.811
TW4 − 0.554 WWTR1 (cg02134705)
TW8 − 0.773 WWTR1 (cg19547293)
TW8 − 0.746 HYAL3;NAT6 (cg13682223)
TW14 0.872
TW5 − 0.707
TW9 0.797 RPTOR (cg08905415)
TW14 − 0.748
TW4 0.615 PIK3CG (cg08779777)
TW16 − 0.505
TW10 − 0.678
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regions of the brain have found distinct differences in
gene expression and DNA methylation patterns [26,
103–105]. Studies have also shown the inconsistencies in
DNA methylation markers from the blood in predicting
brain DNA methylation status [27, 106]. However,
evidence from animal studies have also shown that blood
DNA methylation patterns may in fact reflect patterns in
the brain in a subset of genes [35, 107], suggesting that
peripheral epigenetic marks may reflect disease mecha-
nisms in some cases. Examples where methylation levels
correlate between blood and brain have been reported in
Parkinson’s disease, depression, schizophrenia, bipolar
disorder and autism [107, 108]. The blood is also par-
ticularly useful in investigating disease biomarkers [98]
and is an important peripheral tissue to consider for
neurological disorders, as it is easily accessible to assist
in diagnosis. Another limitation is that our data apply to
twins only, and we cannot yet generalise our findings
more broadly, as there is evidence that risk factors and
associated mechanisms leading to CP may be different
in twins compared to singletons [109]. To overcome
this, our analysis will be repeated in further sets of twins
and singletons. Only with this information can we then
start to put together risk models for predicting CP at the
time of birth. This approach will provide a unique
opportunity to identify a biomarker to predict neurode-
velopmental outcomes such as CP.
Conclusion
This study provides the first evidence that environment-
mediated differential methylation in genes involved in
known processes such as hypoxia and inflammation, and
perhaps processes such as cell adhesion, may contribute
to the development of CP. Our data also pave the way
for larger studies to use DNA methylation data in risk
models to help predict CP before the onset of overt
symptoms and therefore provide a chance for timely
ameliorative interventions.
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